Leerink Partners Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price Target of $115
Benzinga Newsdesk 12 months ago
NewsPrice TargetInitiationAnalyst Ratings
Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating and announces Price Target of $115.
Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating and announces Price Target of $115.